BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16570284)

  • 1. Insulin-like growth factor binding protein 3 as an anticancer molecule in Ewing's sarcoma.
    Benini S; Zuntini M; Manara MC; Cohen P; Nicoletti G; Nanni P; Oh Y; Picci P; Scotlandi K
    Int J Cancer; 2006 Sep; 119(5):1039-46. PubMed ID: 16570284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EWS/Fli-1 chimeric fusion gene upregulates vascular endothelial growth factor-A.
    Nagano A; Ohno T; Shimizu K; Hara A; Yamamoto T; Kawai G; Saitou M; Takigami I; Matsuhashi A; Yamada K; Takei Y
    Int J Cancer; 2010 Jun; 126(12):2790-8. PubMed ID: 19642105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells.
    Girnita L; Girnita A; Wang M; Meis-Kindblom JM; Kindblom LG; Larsson O
    Oncogene; 2000 Aug; 19(37):4298-301. PubMed ID: 10980604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase.
    Zhang S; Guo W; Ren TT; Lu XC; Tang GQ; Zhao FL
    Anticancer Drugs; 2012 Jan; 23(1):108-18. PubMed ID: 21946058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
    Merchant MS; Woo CW; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival.
    Scotlandi K; Manara MC; Serra M; Marino MT; Ventura S; Garofalo C; Alberghini M; Magagnoli G; Ferrari S; Lopez-Guerrero JA; Llombard-Bosch A; Picci P
    Eur J Cancer; 2011 May; 47(8):1258-66. PubMed ID: 21345666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model.
    Chernoguz A; Crawford K; Donovan E; Vandersall A; Berglund C; Cripe TP; Frischer JS
    J Surg Res; 2012 Mar; 173(1):1-9. PubMed ID: 21658718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biological significance of hepatoma-derived growth factor in Ewing's sarcoma.
    Yang Y; Li H; Zhang F; Shi H; Zhen T; Dai S; Kang L; Liang Y; Wang J; Han A
    J Pathol; 2013 Nov; 231(3):323-34. PubMed ID: 23878072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma.
    Fuchs B; Inwards CY; Janknecht R
    Clin Cancer Res; 2004 Feb; 10(4):1344-53. PubMed ID: 14977835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological indicators of prognosis in Ewing's sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP).
    Zambelli D; Zuntini M; Nardi F; Manara MC; Serra M; Landuzzi L; Lollini PL; Ferrari S; Alberghini M; Llombart-Bosch A; Piccolo E; Iacobelli S; Picci P; Scotlandi K
    Int J Cancer; 2010 Jan; 126(1):41-52. PubMed ID: 19544526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects.
    Benini S; Manara MC; Cerisano V; Perdichizzi S; Strammiello R; Serra M; Picci P; Scotlandi K
    Int J Cancer; 2004 Jan; 108(3):358-66. PubMed ID: 14648701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells.
    García-Aragoncillo E; Carrillo J; Lalli E; Agra N; Gómez-López G; Pestaña A; Alonso J
    Oncogene; 2008 Oct; 27(46):6034-43. PubMed ID: 18591936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.
    Asmane I; Watkin E; Alberti L; Duc A; Marec-Berard P; Ray-Coquard I; Cassier P; Decouvelaere AV; Ranchère D; Kurtz JE; Bergerat JP; Blay JY
    Eur J Cancer; 2012 Nov; 48(16):3027-35. PubMed ID: 22682017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The therapeutic and preventive effect of RRR-alpha-vitamin E succinate on prostate cancer via induction of insulin-like growth factor binding protein-3.
    Yin Y; Ni J; Chen M; DiMaggio MA; Guo Y; Yeh S
    Clin Cancer Res; 2007 Apr; 13(7):2271-80. PubMed ID: 17404112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells.
    Scotlandi K; Avnet S; Benini S; Manara MC; Serra M; Cerisano V; Perdichizzi S; Lollini PL; De Giovanni C; Landuzzi L; Picci P
    Int J Cancer; 2002 Sep; 101(1):11-6. PubMed ID: 12209582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model.
    Guan H; Zhou Z; Wang H; Jia SF; Liu W; Kleinerman ES
    Clin Cancer Res; 2005 Apr; 11(7):2662-9. PubMed ID: 15814647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
    Werner S; Mendoza A; Hilger RA; Erlacher M; Reichardt W; Lissat A; Konanz C; Uhl M; Niemeyer CM; Khanna C; Kontny U
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):19-31. PubMed ID: 17823799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells.
    Strammiello R; Benini S; Manara MC; Perdichizzi S; Serra M; Spisni E; Picci P; Scotlandi K
    Horm Metab Res; 2003; 35(11-12):675-84. PubMed ID: 14710346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma.
    Mateo-Lozano S; Gokhale PC; Soldatenkov VA; Dritschilo A; Tirado OM; Notario V
    Clin Cancer Res; 2006 Nov; 12(22):6781-90. PubMed ID: 17121899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition.
    Oh SH; Lee OH; Schroeder CP; Oh YW; Ke S; Cha HJ; Park RW; Onn A; Herbst RS; Li C; Lee HY
    Mol Cancer Ther; 2006 Nov; 5(11):2685-95. PubMed ID: 17121915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.